## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT TRANSMITTAL LETTER

JIN 0 6 2005

APPLICANTS:

Simpson et al.

SERIAL NO .:

10/748,589

FILING DATE:

December 30, 2003

For:

**GROUP ART UNIT: 3763** 

**EXAMINER: Unknown** 

ATTY. DOCKET NO.: EIS-5909H (1417G P 984)

MEDICAL DATA COMMUNICATION AND MESSAGING SYSTEM AND METHOD

Mail Stop: Amendment COMMISSIONER FOR PATENTS P.O. BOX 1450 ALEXANDRIA, VA 22313-1450

When phoning re this application,

please call (847) 948-2000

Dear Sir/Madam:

Submitted herewith is an Information Disclosure Statement for consideration in the above-identified application. This Information Disclosure Statement is submitted:

Within 3 months (1) of filing date of a national application; (2) of date of entry of the national stage as set forth in 37 CFR §1.491 in an international application; or (3) before the mailing date of a first Office Action on the merits, whichever occurs last. (No fee is required.) After the mailing date of a first Office Action but before (1) mailing of a final action under 37 CFR §1.311, whichever occurs first. Please charge payment for the fee set forth in 37 CFR §1.17(i)(1) to Deposit Account No. 02-1440. The certification specified in 37 CFR §1.97(e) is made below. (No fee is required.) After the mailing of (1) a final action under 37 CFR §1.113; or (2) a notice of allowance under 37 CFR §1.311 whichever occurs first, but before payment of the issue fee. The certification specified in 37 CFR §1.97(e) is made below. The Commissioner hereby is petitioned to consider the Information Disclosure Statement accompanying the submission. The undersigned counsel for applicant(s) hereby certifies that the item of information identified in the Information Disclosure Statement was cited in a communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement while all others were already cited in previous Information Disclosure Statements and accompanying documents. The undersigned counsel for applicant(s) hereby certifies that some items of information contained in the Information Disclosure Statement were not cited in a communication from a foreign Patent Office in a counterpart foreign application, or to the knowledge of the undersigned, after making reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of the statement. The Commissioner is hereby authorized to charge any additional fees that may be required, or credit any overpayment to Account No. 02-1440. A duplicate copy of this sheet is enclosed for this purpose.

Very respectfully,

Baxter Healthcare Corporation

Austin J. Foley

Baxter International Ir One Baxter Parkway

Deerfield, Illinois 60015

Telephone: (847) 948-3315

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to the Commissioner for Patents, Arlington VA on June 30, 2005.

Austin J. Foley

Reg. No. 42,543

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE	Docket No:	Appln. No.
(REV. 2-32)	PATENT AND TRADEMARK OFFICE	EIS-5909H (1417G P 984)	10/748,589
	TION DISCLOSURE STATEMENT BY	Applicant:	Examiner:
PE	APPLICANT	Simpson et al.	Unknown
3	se several sheets if necessary)	Filing Date	Group Art
mate w	Sheet 1 of 1	December 30, 2003	3763

<u> </u>	U.S. PATENT DOCUMENTS					
3/2	U.S. Patent Document  Application or  Application or  Application or  Application or  Kind Code					
Examine Initials	Doc. No.	Application or Patent Number	Kind Code	Name of Patentee or Applicant	Date of Publication	Filing Date If Appropriate
_/K.R./	AA	2002/0029776	A1	Blomquist	March 14, 2002	
	-					
			<u> </u>			

·	FOREIGN PATENT DOCUMENTS							
		Foreign Patent Document				Trans	Translation	
Examiner Initials	Doc. No.	Office	Application or Patent Number	Kind Code	Date of Publication	Yes	No*+	
				<u> </u>			<u> </u>	
					-			

OTHER - NON PATENT LITERATURE DOCUMENTS				
Examiner Doc.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item		Translation	
Initials No.		(book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.		
	-			
			ļ	
ļ				

Examiner	Date Considered			
/Kristine Rapillo/	02/04/2010			
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through				
citation if not in conformance and not considered. Include copy of this form with next communication to applicant.				

\* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

<sup>+</sup> An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).